The Pharmacogenetics of Alcohol Use Disorder
- 19 February 2015
- journal article
- review article
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 39 (3) , 391-402
Abstract
Background Annually, the use and abuse of alcohol contributes to millions of deaths and billions of dollars in societal costs. To determine the impact of genetic variation on the susceptibility to the disorder and its response to treatment, studies have been conducted to assess the contribution of a variety of candidate genetic variants. These variants, which we review here, were chosen based upon their observed or hypothesized functional relevance to alcohol use disorder (AUD) risk or to the mechanism by which medications used to treat the disorder exert their effects. Methods This qualitative review examines studies in which candidate polymorphisms were tested as moderator variables to identify pharmacogenetic effects on either the subjective response to alcohol or the outcomes of pharmacotherapy. Results Although findings from these studies provide evidence of a number of clinically relevant pharmacogenetic effects, the literature is limited and there are conflicting findings that require resolution. Conclusions Pharmacogenetic studies of AUD treatment that use greater methodological rigor and better statistical controls, such as corrections for multiple testing, may help to resolve inconsistent findings. These procedures could also lead to the discovery of more robust and clinically meaningful moderator effects. As the field evolves through methodological standardization and the use of larger study samples, pharmacogenetic research has the potential to inform clinical care by enhancing therapeutic effects and personalizing treatments. These efforts may also provide insights into the mechanisms by which medications reduce heavy drinking or promote abstinence in patients with an AUD.Keywords
Funding Information
- NIH (DA030446, AA013736, DA016759)
- Reckitt-Benckiser Pharmaceuticals
- Schering-Plough Corporation
- Johnson & Johnson Pharmaceutical Research & Development
- Endo Pharmaceuticals
- AbbVie
- Alkermes
- Ethypharm
- Lilly
- Lundbeck
- Pfizer
- MediciNova
This publication has 116 references indexed in Scilit:
- Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory StudyNeuropsychopharmacology, 2011
- A Double-Blind, Randomized Trial of Sertraline for Alcohol DependenceJournal of Clinical Psychopharmacology, 2011
- Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology SocietyBehavioural Pharmacology, 2010
- A population-based twin study of the genetic and environmental relationship of major depression, regular tobacco use and nicotine dependencePsychological Medicine, 2010
- Genetic and environmental influences on cannabis use initiation and problematic use: a meta‐analysis of twin studiesAddiction, 2010
- Association of Markers in the 3′ Region of the GluR5 Kainate Receptor Subunit Gene to Alcohol DependenceAlcohol, Clinical and Experimental Research, 2009
- A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.Experimental and Clinical Psychopharmacology, 2009
- Effects of Opioid Receptor Gene Variation on Targeted Nalmefene Treatment in Heavy DrinkersAlcohol, Clinical and Experimental Research, 2008
- An Evaluation of μ-Opioid Receptor (OPRM1) as a Predictor of Naltrexone Response in the Treatment of Alcohol DependenceArchives of General Psychiatry, 2008
- Serotonin Transporter Promoter Gain-of-Function Genotypes Are Linked to Obsessive-Compulsive DisorderThe American Journal of Human Genetics, 2006